PRF as Adjunct to Subgingival Instrumentation in Step 2 Periodontal Therapy

Launched by UNIVERSITY OF BERN · Jun 2, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a treatment called platelet-rich fibrin (PRF) on patients with periodontitis, a serious gum disease that can lead to tooth loss if not treated. The researchers want to see if using PRF alongside standard non-surgical therapy can help improve healing and attachment of the gums to the teeth over a period of six months. PRF is derived from the patient's own blood and has properties that may promote healing and reduce inflammation.

To participate in this study, you must be at least 18 years old and have moderate to severe periodontitis, with at least 20 natural teeth. You also need to be willing to complete the study and provide informed consent. If you have had recent dental treatments, are pregnant, or have certain medical conditions, you may not be eligible. If you join, you'll receive treatment and follow-ups over six months to see how well the PRF works in improving your gum health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Men and women aged ≥ 18 years
• • Periodontitis stage II-IV, grade A/B/C, generalized
• • Presence of at least 20 teeth (excluding wisdom teeth)
• • Absence of removable dentures
• • Patients willing to provide written informed consent and to complete the 6- month study follow-up
• Exclusion Criteria:
• • Patients already participating in other clinical trials
• • Periodontal treatment in the previous 12 months
• • Antibiotic treatment 3 months prior to study entry
• • Antibiotic prophylaxis required for dental treatment
• • Current use of any medication that may affect the clinical features of periodontitis
• • Pregnant/lactating
• • Any condition that prevents venipuncture
• • Not willing to venous puncture
• • Current cancer treatment
• • History of radiation in the head-neck area